• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Solid Biosciences Inc.

    11/1/24 4:10:37 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SLDB alert in real time by email
    SC 13G/A 1 SLDB_SC13GA1.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    (AMENDMENT NO. 1)

    SOLID BIOSCIENCES INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.001 PER SHARE
    (Title of Class of Securities)

    83422E204
    (CUSIP Number)

    SEPTEMBER 30, 2024
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    83422E204

    SCHEDULE 13G

    Page  
    2
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,117,097
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,117,097
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,117,097
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     2.9%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    83422E204

    SCHEDULE 13G

    Page  
    3
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,117,097
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,117,097
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,117,097
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     2.9%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    83422E204

    SCHEDULE 13G

    Page  
    4
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,117,097
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,117,097
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,117,097
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     2.9%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    83422E204

     SCHEDULE 13G

    Page  
    5
      of   
    10
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      Solid Biosciences Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    500 Rutherford Avenue, Third Floor
    Charlestown, Massachusetts 02129

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.001 per share ("Common Stock")
     
      (e) CUSIP Number:
    83422E204
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    83422E204

     SCHEDULE 13G

    Page  
    6
      of   
    10
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    83422E204

     SCHEDULE 13G

    Page  
    7
      of   
    10

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    83422E204

    SCHEDULE 13G

    Page  
    8
      of   
    10

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of October 31, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    83422E204

    SCHEDULE 13G

    Page  
    9
      of   
    10
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: October 31, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    83422E204

    SCHEDULE 13G

    Page  
    10
      of   
    10
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.001 per share, of Solid Biosciences Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: October 31, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $SLDB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLDB

    DatePrice TargetRatingAnalyst
    1/8/2025$16.00Buy
    Truist
    12/13/2024$16.00Outperform
    Wedbush
    12/10/2024$15.00Mkt Outperform
    JMP Securities
    7/15/2024$10.00 → $15.00Neutral → Overweight
    JP Morgan
    6/24/2024$12.00Market Perform → Outperform
    Leerink Partners
    5/31/2024$20.00Overweight
    Piper Sandler
    3/28/2024$40.00Outperform
    William Blair
    3/15/2024$16.00Buy
    Citigroup
    More analyst ratings

    $SLDB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

      SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 7:59:25 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Solid Biosciences Inc.

      SC 13G - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 12:02:53 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Solid Biosciences Inc.

      SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)

      11/14/24 8:56:19 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Solid Biosciences with a new price target

      Truist initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00

      1/8/25 8:30:04 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Solid Biosciences with a new price target

      Wedbush initiated coverage of Solid Biosciences with a rating of Outperform and set a new price target of $16.00

      12/13/24 8:18:51 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Solid Biosciences with a new price target

      JMP Securities initiated coverage of Solid Biosciences with a rating of Mkt Outperform and set a new price target of $15.00

      12/10/24 8:02:56 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Financials

    Live finance-specific insights

    See more
    • Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

      — Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential cardiac benefit observed ——SGT-003 has been well-tolerated in the 6 participants dosed as of February 11, 2025, with no serious adverse events observed —— Participant enrollment continues, with the 7th participant dosed on February 17, 2025; Company expects to dose approximately 20 total participants

      2/18/25 6:45:43 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

      - SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia - - Dual route of administration enables direct delivery of AAV-based gene therapy to the cerebellum and heart to potentially address the most significant symptoms of the disease - - Phase 1b clinical trial initiation expected in 2H 2025 - - Company to hold a conference call tomorrow, January 8, 2025, at 8:30 AM ET - CHARLESTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today a

      1/7/25 4:15:00 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

      - Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - - Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with Duchenne; Anticipated dosing in late – 2023, subject to IND clearance - - Company ends 2022 with approximately $213.7 million in cash and investments; Anticipated cash runway into 2025 - CHARLESTOWN, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financ

      3/23/23 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 81,000 restricted stock units ("RSUs") to seven newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducemen

      5/1/25 4:00:00 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences to Participate at The Citizens Life Sciences Conference

      CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 30 days on the Events page. Institutional investors interested in meeting with management during the conference may reach out to thei

      4/30/25 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting

      CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), from May 13-17, 2025, in New Orleans, LA. "The data we will present at this year's ASGCT Annual Meeting reflect Solid's significant advances in next-generation capsid design and therapeutic approach for Duchenne, in

      4/29/25 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Solid Biosciences Inc.

      DEFA14A - Solid Biosciences Inc. (0001707502) (Filer)

      4/25/25 4:03:30 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Solid Biosciences Inc.

      DEF 14A - Solid Biosciences Inc. (0001707502) (Filer)

      4/25/25 4:01:30 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Solid Biosciences Inc.

      PRE 14A - Solid Biosciences Inc. (0001707502) (Filer)

      4/11/25 5:03:57 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smith Ian F converted options into 4,574 shares, increasing direct ownership by 4% to 117,546 units (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      4/8/25 4:05:03 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kahn Clare bought $9,924 worth of shares (1,860 units at $5.34), increasing direct ownership by 169% to 2,960 units (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      3/13/25 4:05:03 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Bain Capital Life Sciences Investors, Llc bought $4,030,000 worth of shares (1,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 5:48:02 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Solid Biosciences Provides Third Quarter Business Update and Financial Results

      – IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter with approximately $142.9 million in cash and investments; Anticipated cash runway through multiple important pipeline milestones and into 2025 – CHARLESTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update. "We are pleased with the continued advanceme

      11/8/23 4:17:49 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

      - Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid's focus on both neuromuscular and cardiac diseases - CHARLESTOWN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for both neuromuscular and cardiac diseases, today announced the appointment of Gabriel Brooks, M.D., as Chief Medical Officer. "We are excited to welcome Dr. Brooks to Solid Biosciences during this pivotal time in our company's history, advancing towards the clinic with our next generation gene therapy for Duc

      10/2/23 8:00:00 AM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SLDB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kahn Clare bought $9,924 worth of shares (1,860 units at $5.34), increasing direct ownership by 169% to 2,960 units (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      3/13/25 4:05:03 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Bain Capital Life Sciences Investors, Llc bought $4,030,000 worth of shares (1,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 5:48:02 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Perceptive Advisors Llc bought $20,150,000 worth of shares (5,000,000 units at $4.03) (SEC Form 4)

      4 - Solid Biosciences Inc. (0001707502) (Issuer)

      2/21/25 4:17:42 PM ET
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care